309 related articles for article (PubMed ID: 25855603)
1. PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia.
Dang J; Wei L; de Ridder J; Su X; Rust AG; Roberts KG; Payne-Turner D; Cheng J; Ma J; Qu C; Wu G; Song G; Huether RG; Schulman B; Janke L; Zhang J; Downing JR; van der Weyden L; Adams DJ; Mullighan CG
Blood; 2015 Jun; 125(23):3609-17. PubMed ID: 25855603
[TBL] [Abstract][Full Text] [Related]
2. B Cell Linker Protein (BLNK) Is a Selective Target of Repression by PAX5-PML Protein in the Differentiation Block That Leads to the Development of Acute Lymphoblastic Leukemia.
Imoto N; Hayakawa F; Kurahashi S; Morishita T; Kojima Y; Yasuda T; Sugimoto K; Tsuzuki S; Naoe T; Kiyoi H
J Biol Chem; 2016 Feb; 291(9):4723-31. PubMed ID: 26703467
[TBL] [Abstract][Full Text] [Related]
3. PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice.
Jamrog L; Chemin G; Fregona V; Coster L; Pasquet M; Oudinet C; Rouquié N; Prade N; Lagarde S; Cresson C; Hébrard S; Nguyen Huu NS; Bousquet M; Quelen C; Brousset P; Mancini SJC; Delabesse E; Khamlichi AA; Gerby B; Broccardo C
Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10357-10362. PubMed ID: 30257940
[No Abstract] [Full Text] [Related]
4. Pax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia.
Liu GJ; Cimmino L; Jude JG; Hu Y; Witkowski MT; McKenzie MD; Kartal-Kaess M; Best SA; Tuohey L; Liao Y; Shi W; Mullighan CG; Farrar MA; Nutt SL; Smyth GK; Zuber J; Dickins RA
Genes Dev; 2014 Jun; 28(12):1337-50. PubMed ID: 24939936
[TBL] [Abstract][Full Text] [Related]
5. The reduced and altered activities of PAX5 are linked to the protein-protein interaction motif (coiled-coil domain) of the PAX5-PML fusion protein in t(9;15)-associated acute lymphocytic leukemia.
Qiu JJ; Chu H; Lu X; Jiang X; Dong S
Oncogene; 2011 Feb; 30(8):967-77. PubMed ID: 20972455
[TBL] [Abstract][Full Text] [Related]
6. Activating PAX gene family paralogs to complement PAX5 leukemia driver mutations.
Hart MR; Anderson DJ; Porter CC; Neff T; Levin M; Horwitz MS
PLoS Genet; 2018 Sep; 14(9):e1007642. PubMed ID: 30216339
[TBL] [Abstract][Full Text] [Related]
7. PAX5 is part of a functional transcription factor network targeted in lymphoid leukemia.
Okuyama K; Strid T; Kuruvilla J; Somasundaram R; Cristobal S; Smith E; Prasad M; Fioretos T; Lilljebjörn H; Soneji S; Lang S; Ungerbäck J; Sigvardsson M
PLoS Genet; 2019 Aug; 15(8):e1008280. PubMed ID: 31381561
[TBL] [Abstract][Full Text] [Related]
8. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia.
Heltemes-Harris LM; Willette MJ; Ramsey LB; Qiu YH; Neeley ES; Zhang N; Thomas DA; Koeuth T; Baechler EC; Kornblau SM; Farrar MA
J Exp Med; 2011 Jun; 208(6):1135-49. PubMed ID: 21606506
[TBL] [Abstract][Full Text] [Related]
9. Comparative genomics reveals multistep pathogenesis of E2A-PBX1 acute lymphoblastic leukemia.
Duque-Afonso J; Feng J; Scherer F; Lin CH; Wong SH; Wang Z; Iwasaki M; Cleary ML
J Clin Invest; 2015 Sep; 125(9):3667-80. PubMed ID: 26301816
[TBL] [Abstract][Full Text] [Related]
10. Expression and production of aberrant PAX5 with deletion of exon 8 in B-lineage acute lymphoblastic leukaemia of children.
Sadakane Y; Zaitsu M; Nishi M; Sugita K; Mizutani S; Matsuzaki A; Sueoka E; Hamasaki Y; Ishii E
Br J Haematol; 2007 Jan; 136(2):297-300. PubMed ID: 17129225
[TBL] [Abstract][Full Text] [Related]
11. The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party.
Iacobucci I; Lonetti A; Paoloni F; Papayannidis C; Ferrari A; Storlazzi CT; Vignetti M; Cilloni D; Messa F; Guadagnuolo V; Paolini S; Elia L; Messina M; Vitale A; Meloni G; Soverini S; Pane F; Baccarani M; Foà R; Martinelli G
Haematologica; 2010 Oct; 95(10):1683-90. PubMed ID: 20534699
[TBL] [Abstract][Full Text] [Related]
12. Biphenotypic B-lymphoid/myeloid cells expressing low levels of Pax5: potential targets of BAL development.
Simmons S; Knoll M; Drewell C; Wolf I; Mollenkopf HJ; Bouquet C; Melchers F
Blood; 2012 Nov; 120(18):3688-98. PubMed ID: 22927250
[TBL] [Abstract][Full Text] [Related]
13. EBF1 and Pax5 safeguard leukemic transformation by limiting IL-7 signaling, Myc expression, and folate metabolism.
Ramamoorthy S; Kometani K; Herman JS; Bayer M; Boller S; Edwards-Hicks J; Ramachandran H; Li R; Klein-Geltink R; Pearce EL; Grün D; Grosschedl R
Genes Dev; 2020 Nov; 34(21-22):1503-1519. PubMed ID: 33004416
[No Abstract] [Full Text] [Related]
14. The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.
Schinnerl D; Fortschegger K; Kauer M; Marchante JR; Kofler R; Den Boer ML; Strehl S
Blood; 2015 Feb; 125(8):1282-91. PubMed ID: 25515960
[TBL] [Abstract][Full Text] [Related]
15. PAX5 fusion genes in acute lymphoblastic leukemia: A literature review.
Fouad FM; Eid JI
Medicine (Baltimore); 2023 May; 102(20):e33836. PubMed ID: 37335685
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of inflammatory signaling in Pax5 mutant cells mitigates B-cell leukemogenesis.
Isidro-Hernández M; Mayado A; Casado-García A; Martínez-Cano J; Palmi C; Fazio G; Orfao A; Ribera J; Ribera JM; Zamora L; Raboso-Gallego J; Blanco O; Alonso-López D; De Las Rivas J; Jiménez R; García Criado FJ; García Cenador MB; Ramírez-Orellana M; Cazzaniga G; Cobaleda C; Vicente-Dueñas C; Sánchez-García I
Sci Rep; 2020 Nov; 10(1):19189. PubMed ID: 33154497
[TBL] [Abstract][Full Text] [Related]
17. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia.
Shah S; Schrader KA; Waanders E; Timms AE; Vijai J; Miething C; Wechsler J; Yang J; Hayes J; Klein RJ; Zhang J; Wei L; Wu G; Rusch M; Nagahawatte P; Ma J; Chen SC; Song G; Cheng J; Meyers P; Bhojwani D; Jhanwar S; Maslak P; Fleisher M; Littman J; Offit L; Rau-Murthy R; Fleischut MH; Corines M; Murali R; Gao X; Manschreck C; Kitzing T; Murty VV; Raimondi S; Kuiper RP; Simons A; Schiffman JD; Onel K; Plon SE; Wheeler D; Ritter D; Ziegler DS; Tucker K; Sutton R; Chenevix-Trench G; Li J; Huntsman DG; Hansford S; Senz J; Walsh T; Lee M; Hahn CN; Roberts K; King MC; Lo SM; Levine RL; Viale A; Socci ND; Nathanson KL; Scott HS; Daly M; Lipkin SM; Lowe SW; Downing JR; Altshuler D; Sandlund JT; Horwitz MS; Mullighan CG; Offit K
Nat Genet; 2013 Oct; 45(10):1226-1231. PubMed ID: 24013638
[TBL] [Abstract][Full Text] [Related]
18. PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia.
Bastian L; Schroeder MP; Eckert C; Schlee C; Tanchez JO; Kämpf S; Wagner DL; Schulze V; Isaakidis K; Lázaro-Navarro J; Hänzelmann S; James AR; Ekici A; Burmeister T; Schwartz S; Schrappe M; Horstmann M; Vosberg S; Krebs S; Blum H; Hecht J; Greif PA; Rieger MA; Brüggemann M; Gökbuget N; Neumann M; Baldus CD
Leukemia; 2019 Aug; 33(8):1895-1909. PubMed ID: 30842609
[TBL] [Abstract][Full Text] [Related]
19. EBF1 and PAX5 control pro-B cell expansion via opposing regulation of the Myc gene.
Somasundaram R; Jensen CT; Tingvall-Gustafsson J; Åhsberg J; Okuyama K; Prasad M; Hagman JR; Wang X; Soneji S; Strid T; Ungerbäck J; Sigvardsson M
Blood; 2021 Jun; 137(22):3037-3049. PubMed ID: 33619557
[TBL] [Abstract][Full Text] [Related]
20. Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP-BFM acute lymphoblastic leukemia protocol.
Jung M; Schieck M; Hofmann W; Tauscher M; Lentes J; Bergmann A; Stelter M; Möricke A; Alten J; Schlegelberger B; Schrappe M; Zimmermann M; Stanulla M; Cario G; Steinemann D
Genes Chromosomes Cancer; 2020 Nov; 59(11):667-671. PubMed ID: 32592278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
